Behavioral Neuroscience – News and Features

The three-month monotherapy trial with PRX-03140 to evaluate impact on cognitive function.

Biotech innovators will contribute to international effort to produce most detailed map of genetic variation.

The newly issued patent further expands the domain of previously issued patents to include multiple disease states related to nervous systems disorders.

According to scientists, findings may help to match smokers with treatments most likely to help them quit.

Non-hereditary genetic variations may help explain illness's evolutionary staying power, researchers say.

Agilent will supply custom oligonucleotide microarrays to Signature and its customers based on the Signature-designed SignatureChip Oligo Solution.

Collaboration of scientists from the University of Utah and Vanderbilt University looks to gain insights for the diagnosis of multiple sclerosis (ms) and autism.

A nationwide consortium led by the University of Washington has completed the first sequence-based map of structural variations in the human genome.

The work, published in the journal "Nature", provides a starting point to examine how such DNA variation contributes to human health and disease.

The Phase III trial is a multi-center, double-blind, placebo-controlled study to evaluate the safety and efficacy of pimavanserin.